Thank you for the opportunity to review this well-written manuscript, titled 'The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system'. This manuscript maps the RX-RISK pharmaceutical measure of patient comorbidity to the WHO's ATC list of medicines, to facilitate future research u sing this tool. The authors also assess the validity of the RX RISK tool by comparing its performance across different conditions.
General comments:
• Minor point -but the term 'multimorbidity' does not require a hyphen.
• Are the authors aware of other research which has looked at the validity of the RX-RISK tool? Do weights not already exist for that tool? If so, why do we need new ones? This needs to be made much clearer in the paper…i.e. why is it important to validate this tool again? What do we stand to miss if we just use the original weights? This needs to be 'sold' a bit stronger.
• Based on how the authors have framed the Introduction, I believe that the study actually has two aims -the first is to present a map between the RX RISK tool and the WHO's ATC list of medicines; and the second is to assess the validity of the RX RISK tool in terms of one-year mortality, by comparing it's performance across different conditions.
• Is there a difference between the RX RISK-V and the RX RISK tool used by the authors in the study? If not, I would suggest consistent language (to prevent confusion). I note that the authors say in the Introduction that the latest version of the RX RISK-V tool has 42 conditions, but the author's version has 46 conditions. Please clarify this in the text.
• When introducing the primary data source, I think it would be useful to mention why it is necessary to have two data sources. I assume the purpose of the first data source was to help you determine your weights for each condition -and the second data source can be used to determine whether those weights hold-true for a separate (actually quite different…too different?) population. But reading-on in the paper, it looks like you calculated weights for the second population too…which, in my opinion, stops them from being a validation dataset and turns them into being a second primary (!) dataset. Can the authors clarify why they calculated two different sets of weights? If the authors needed to calculate two different sets of weights, then doesn't that technically mean that the weights determined in the first dataset were not valid? o If the authors are going to present two different sets of weights, it needs to be much clearer when an author should use one set of weights and when they should use the other. The authors need to expand on this and clarify….beginning with the reason why two data sources were needed in the first place (if you were going to essentially develop two different sets of weights).
• The authors say: 'Analysis was restricted to veterans who were DVA Gold Card holders prior to 1 July 2013 (ensuring they were eligible for all DVA subsidised services, thus the data set captured all their health claims), and were between the ages of 65 and 100 years at 1 January 2015 (N=135,406).' What can the authors tell us about those who were excluded because of the Gold Card (including how many were excluded)? How might these exclusions affect the applicability of the results observed in this population to others in this age group (i.e. we aren't just looking at those aged 75+, but a certain 'type' of person who is aged 75+)? • Did the authors exclude those who died prior to 2015? If so, please say so.
• The authors need to provide more information about how their weights were calculated. They have described the 'bits' that are used to calculate these weights, but not how the weights were actually calculated. Please do so.
• I'm not convinced that the comparators used to investigate the validity of the RX-RISK tool are entirely useful. Why would the total number of medicines prescribed over a certain period of time be a valid indicator of the level of comorbidity? Has this been done previously? It strikes me as a trifle unfair -rather stacking the odds in favour of the RX-RISK (which looks at individual comorbidities, as opposed to a simple pan-comorbidity count of prescriptions). The authors need to clarify the value of their comparators, and add citations if this method has been done before.
• An extra sentence is required explaining how the individual comorbidities were included in the model -I assume each comorbidity was individually added to the model, but please make this obvious.
• The authors need to include an ethics statement -including information about de-identification/anonymity of the data that they used.
• It perhaps makes sense that the model including the individual comorbidities performed the best -since the model had more information than a single representative value (i.e. a score). In the Discussion, the authors say: 'In practice, Rx-Risk treated as individual covariates may be more easily applied, however, the weighted score may be a better option when sample sizes are smaller taking up fewer degrees of freedom.' However, that is not the only (nor primary) reason why it is useful to use comorbidity indices/scores. The value of a comorbidity score is in presenting an individual's (or population's) level of comorbidity in one aggregate measure -rather than needing to include all of the separate conditions that comprise the score. There are multiple benefits to this aggregation, of which degrees of freedom in a regression model is only one. Therefore, I'm not convinced that comparing the index's performance with a model that included all of the individual conditions is a strong indicator of the validity of the index…the question then becomes: valid compared to what? It is more typical to compare index-to-index -for example, Charlson to Elixhauser. Perhaps the authors could clarify the value of including the individual conditions as an extra model -or consider removing this aspect from the analysis.
• Building on the point above -the authors refer to the individual comorbidities in the last paragraph of the results as 'RxRisk index treated as individual covariates'. This measure is no longer the RX-RISK -just the conditions that comprise that index. It can't be thought of as being the RX-RISK in another form.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Štefan Bojnec Institution and Country: University of Primorska, Slovenia Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below This manuscript aims to investigate the validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system.
1) The manuscript lacks clear presentation of motivation, possible novelty and/or contribution. Response: Our motivation was to both present the map of ATC codes to the Rx Risk categories and to validate the use of the RxRisk score as a comorbidity score. The mapping of ATC codes to RxRisk categories has never been published and this will be highly valuable to researchers using pharmacy claims data. Additionally our validation of the RxRisk score will be useful as an additional tool to complement other comorbidity indexes based on diagnosis codes alone. We have amended our objectives to address this point. We have also amended a sentence in the introduction to read "A list of Rx-Risk comorbidities and their corresponding medicines mapped to a standardised international coding system has not been published previously and would facilitate use of the index across health systems."
2) The study is based on a single year, which is not up-to-date. Response: The study year used was based on available data and could be updated in future research. We do not believe that the year used will bias our results and results should be applicable to current patterns of use.
3) Data section lacks clarity, which is valid for manuscript as a whole. Missing are basic descriptive statistics with better explanation of the variables used. Response: Basic descriptive statistics of our cohorts are available in the text under the heading Data Sources. The variables used in the calculation of the RxRisk score are listed in Table 1. 4) There are more limitations of this study than there are mentioned (only two), e.g. data from 2013-2014: how they are relevant in 2018?
Response: We agree with the reviewer that it would have been preferable to include more contemporary data. Unfortunately the prescribing data available for use do contain a lag and we required 1 year of follow-up to determine death status. As mentioned above we intend to update these results as new data become available.
5) Why logist model was selected, but it is only briefly reported? Response: Logistic regression was chosen as it is the standard method of assessment for validity studies, and has been used in previous validity studies using RxRisk. This is appropriate for comparative purposes.
6) What are implications?
Response: We have amended our discussion comments to address the implications of our work specifically, we discuss the use of the RxRisk as a tool to help account for potential confounding in observational studies using pharmacy claims data.
7) Conclusion is very brief.
Response: We have amended our conclusion. We believe this conclusion now highlights the main finding of our study and how the work can be used in practice.
8) There is a limited liste of relevant references. Response: We believe that we have included all the relevant references. The use of RxRisk has been limited, presumably because there is currently not published list of medicines codes mapped to the RxRisk categories -a gap we hope to fill with our manuscript. Table 1 is on more pages: what is its focus and novelty/contribution,? Response: As per comment 1 we believe that Table 1 is important as it provides the mapping of ATC codes to individual comorbidities in the RxRisk. Additionally this Table provides the weights required for other researchers to use in their studies. Perhaps this can be rectified in the editorial process and reproduced in a landscape format. Table 2 the scalling system for weighted Rx-Ris score with "0, -1, 1, ..., 6)? Response: The weights listed in Table 2 refer to the weight given to each of the corresponding RxRisk categories. The unweighted RxRisk score is simply a sum of the conditions that the patient has (that is each condition is given equal weight and simply summed). The weighted score, on the other hand, is a sum of the "weights" for all the conditions that the patient has. For example, the RxRisk score for a patient who has Pain and Renal disease is 2, that is they have 2 of the RxRisk conditions while their weighted Rx Score is 9 that is the sum of the weight for Pain (3) and Renal Disease (6). The weights are assigned based on the magnitude of the association between that comorbidity and the odds of death built based on the entire population. To clarify this point we have added the following to the methods section: "As an example, the unweighted RxRisk score for a patient who has two comorbidities 'Pain' and 'Renal disease' is 2, while their weighted Rx Score is 9 that is the sum of the weight for 'Pain' (3) and 'Renal Disease' (6) ." Table 3 are not reported some basic statistics. It is also not clear where are presented results of logistic regressions? Response: As the aim of this analysis was to determine the predictive ability of the RxRisk score the appropriate results from the logistic regression model are the AICs and C-statistics generated from these models. These are the results of the logistic regression model and are found in Table 3 . As mentioned above the basic descriptive statistics of the cohorts are found in the text under the heading Data Sources.
9) Big
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Reviewer: 2 Reviewer Name: Kris Jamsen Institution and Country: d3 Medicine, A Certara Company, Australia Please state any competing interests or state 'None declared': None declared.
Please leave your comments for the authors below The authors have performed a rigorous evaluation of the predictive properties of Rx-Risk with respect to mortality in older outpatient populations. The overall strategy for addressing the objective is clear, however, I have one major comment.
It appears that the weighted Rx-Risk was calculated by entering the 43 comorbidity indicators (yes/no) to a logistic regression model with mortality as the outcome and age and gender as covariates. So, this implies that the resulting weights for the individual comorbidities account for age and gender. However, in the statistical analysis, it appears that models with weighted Rx-Risk were adjusted for age and gender. This seems redundant, since the weights already account for age and gender. As such, I think it would be useful to perform the analysis of the weighted Rx-Risk without age and gender adjustment. Or perhaps, do this as a sensitivity analysis. Response: We thank the reviewer for his insightful comments. Other studies have used a similar method to us [see Quan H. et al. Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data from 6 Countries, Am J Epi 2011 and reference [7] in our paper] in which age and gender are included in the model used to calculate weights and are also included in the model which includes the weighted summary score. However, based on this comment we have rerun our analyses in which we excluded the adjustment for age and sex from the model in which the weights are derived. The results of this analysis showed that the model fit using weights derived from the unadjusted model in the DVA data and applied to the external PBS dataset was not as good (c-stat 77.9% 95% CI 88.5% -78.3% and AIC 76823) as the model in which we adjusted for age and sex (c-statistic 79.1% 95% CI 78.8% -79.5% and AIC 75692). More importantly we believe that the model in which the odds ratios are calculated and from which the weights are derived should include the adjustment for age and sex. This is especially true when the purpose is to calculate weights which are generalizable to other settings which have a different age/sex profile. We believe adjusted weights are required and therefore have not included the unadjusted results in our manuscript.
Also, I think that for the weighted Rx-Risk, validation should focus on the data that were not used to derive the weights (i.e., external validation). It seems that the key purpose of an internal validation of the weighted Rx-Risk, using the data the weights were derived from, would be to ensure accuracy in the weights. Response: We have amended our results by removing the calculation of the weights in the PBS data.
Once these issues are addressed, I'd be happy to reassess the manuscript. Also, if I have misunderstood anything, please advise.
Reviewer: 3 Reviewer Name: Jason Gurney Institution and Country: University of Otago, Wellington, New Zealand Please state any competing interests or state 'None declared': None declared.
Please leave your comments for the authors below Review for BMJ Open -Manuscript ID# 2017-021122 Thank you for the opportunity to review this well-written manuscript, titled 'The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system'. This manuscript maps the RX-RISK pharmaceutical measure of patient comorbidity to the WHO's ATC list of medicines, to facilitate future research u sing this tool. The authors also assess the validity of the RX RISK tool by comparing its performance across different conditions.
General comments:
• Minor point -but the term 'multimorbidity' does not require a hyphen. Response: Thank you we have removed the hyphen throughout
•
Are the authors aware of other research which has looked at the validity of the RX-RISK tool? Do weights not already exist for that tool? If so, why do we need new ones? This needs to be made much clearer in the paper…i.e. why is it important to validate this tool again? What do we stand to miss if we just use the original weights? This needs to be 'sold' a bit stronger. Response: The validity of the RxRisk score has been published previously [see Reference [8] , Vitry et al. and reference [7] ] however as we mentioned in our introduction, medication is a rapidly changing landscape with many new treatments becoming available to treat chronic disease. We feel that this update is timely and will be a useful reference for other researchers. Other studies using the RxRisk have used older versions of the tool that have not included diseases such as hepatitis etc as there were no treatments previously available for them. Also previous published weights for the RxRisk score were calculated by predicting cost of treatment rather than risk of death as we have done. Another study calculated weights for predicting death however this was done in a selected population (that is those using NSAIDs in 2002 (reference [7] in out manuscript). In studies in observational data the RxRisk can be used as a tool to help adjust for confounding, therefore a model based on weights that are a better predictor of death (rather than cost) are of value as is our update of the conditions treated with contemporary medicines. In our introduction we state: "Due to continual advances in pharmaceutical disease management and as new medicines are used to treat particular diseases, e.g. treatment for hepatitis B and C, the RxRisk requires periodical updating and re-validation. A list of Rx-Risk comorbidities and their corresponding medicines mapped to a standardised international coding system would facilitate use of the index across health systems."
• Based on how the authors have framed the Introduction, I believe that the study actually has two aims -the first is to present a map between the RX RISK tool and the WHO's ATC list of medicines; and the second is to assess the validity of the RX RISK tool in terms of one-year mortality, by comparing it's performance across different conditions. Response: Reviewer 1 has also commented on this. We have more clearly defined our objective to highlight that we have these two aims.
• Is there a difference between the RX RISK-V and the RX RISK tool used by the authors in the study? If not, I would suggest consistent language (to prevent confusion). I note that the authors say in the Introduction that the latest version of the RX RISK-V tool has 42 conditions, but the author's version has 46 conditions. Please clarify this in the text. Response: The original RxRisk-V tool did have 42 conditions, however as mentioned above the new tool we have validated contains 46 conditions to account for new conditions that now have a therapeutic treatment. We have tried to be consistent by referring to this new score as RxRisk (without the -V subscript) to clearly define these different scores.
• When introducing the primary data source, I think it would be useful to mention why it is necessary to have two data sources. I assume the purpose of the first data source was to help you determine your weights for each condition -and the second data source can be used to determine whether those weights hold-true for a separate (actually quite different…too different?) population. But reading-on in the paper, it looks like you calculated weights for the second population too…which, in my opinion, stops them from being a validation dataset and turns them into being a second primary (!) dataset. Can the authors clarify why they calculated two different sets of weights? If the authors needed to calculate two different sets of weights, then doesn't that technically mean that the weights determined in the first dataset were not valid? Response: As per comment 2 reviewer #2 we have clarified that the purpose of our analysis was to derive the weights in the first dataset and determine their applicability in an external dataset. We have removed the weights derived from the PPBS data in Table 1 and removed the corresponding validation results in Table 3 . Under Data Sources section in the methods we have stated that the PBS data was used for external validation.

If the authors are going to present two different sets of weights, it needs to be much clearer when an author should use one set of weights and when they should use the other. The authors need to expand on this and clarify….beginning with the reason why two data sources were needed in the first place (if you were going to essentially develop two different sets of weights). Response: We have removed the weights generated using the external PBS dataset.
• The authors say: 'Analysis was restricted to veterans who were DVA Gold Card holders prior to 1 July 2013 (ensuring they were eligible for all DVA subsidised services, thus the data set captured all their health claims), and were between the ages of 65 and 100 years at 1 January 2015 (N=135,406).' What can the authors tell us about those who were excluded because of the Gold Card (including how many were excluded)? How might these exclusions affect the applicability of the results observed in this population to others in this age group (i.e. we aren't just looking at those aged 75+, but a certain 'type' of person who is aged 75+)?
Response: We thank the reviewer for picking this up. The majority (91%) of the DVA population over 65 were Gold Card Holders. It was necessary to make this restriction as only Gold Card Holders will have recorded data for all their health care services and medicines. This population is likely to representative of the elderly population as the 9% who were not included had a similar mean age of 81 (compared to a mean age of 83 in the Gold card holders).
• Did the authors exclude those who died prior to 2015? If so, please say so. Response: We have amended our description in the methods to clarify this point: "The primary outcome for this study was death recorded in 2015, hence patients we only included if they were alive as at 1 January 2015."
•
The authors need to provide more information about how their weights were calculated. They have described the 'bits' that are used to calculate these weights, but not how the weights were actually calculated. Please do so. Response: Please see response to Reviewer 1 (comment #10) who also raised this issue.
• I'm not convinced that the comparators used to investigate the validity of the RX-RISK tool are entirely useful. Why would the total number of medicines prescribed over a certain period of time be a valid indicator of the level of comorbidity? Has this been done previously? It strikes me as a trifle unfair -rather stacking the odds in favour of the RX-RISK (which looks at individual comorbidities, as opposed to a simple pan-comorbidity count of prescriptions). The authors need to clarify the value of their comparators, and add citations if this method has been done before. Response: A simple count of the number of distinct prescription medicines has been used previously in studies validating chronic disease scores using prescription claims data as a crude comorbidity measure. For example Schneeweiss et al. Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies using Claims Data. Am J Epi 2001 and a previous RxRisk validation paper (reference [7] in our manuscript)
• An extra sentence is required explaining how the individual comorbidities were included in the model -I assume each comorbidity was individually added to the model, but please make this obvious. Response: The reviewer is correct each comorbidity category was entered into the model using binary indicators for presence (1) or absence (0) of medicines used to treat that disease. The following sentence has been added to the Statistical Analysis Section: "Models using the individual comorbidities were developed with an indicator variable included for the presence (1) or absence (0) of each individual RxRisk category."
The authors need to include an ethics statement -including information about deidentification/anonymity of the data that they used. Response: This research was approved by the Australian Government Department of Veterans' Affairs (DVA) Human Research Ethics Committee and the University of South Australia Human Research Ethics Committee
It perhaps makes sense that the model including the individual comorbidities performed the best -since the model had more information than a single representative value (i.e. a score). In the Discussion, the authors say: 'In practice, Rx-Risk treated as individual covariates may be more easily applied, however, the weighted score may be a better option when sample sizes are smaller taking up fewer degrees of freedom.' However, that is not the only (nor primary) reason why it is useful to use comorbidity indices/scores. The value of a comorbidity score is in presenting an individual's (or population's) level of comorbidity in one aggregate measure -rather than needing to include all of the separate conditions that comprise the score. There are multiple benefits to this aggregation, of which degrees of freedom in a regression model is only one. Therefore, I'm not convinced that comparing the index's performance with a model that included all of the individual conditions is a strong indicator of the validity of the index…the question then becomes: valid compared to what? It is more typical to compare index-to-index -for example, Charlson to Elixhauser. Perhaps the authors could clarify the value of including the individual conditions as an extra model -or consider removing this aspect from the analysis. Response: We agree with the reviewer and have extensively amended our limitations paragraph in the discussion. (last paragraph before the conclusion)
